LENSAR, Inc.
NNASDAQ:LNSRRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- LENSAR, Inc. (NASDAQ: LNSR) designs, develops, and markets advanced femtosecond laser systems for refractive cataract surgery and astigmatism management; its core offerings include the ALLY Robotic Cataract Laser Treatment System, a compact platform enabling sterile, single-room procedures with AI-integrated imaging and proprietary Streamline software for precision capsulotomy, lens fragmentation, corneal incisions, and astigmatism correction; the legacy LENSAR Laser System with IntelliAxis and Streamline IV technologies for automated 3D imaging, procedure planning, and efficiency enhancements; and associated consumable components such as disposable procedure kits. The company targets ophthalmic surgeons and surgery centers, generating the majority of revenue from the United States, with additional operations in Europe and Asia. Founded in 2004 and headquartered at 2800 Discovery Drive in Orlando, Florida, LENSAR focuses on robotic technologies to improve clinical outcomes, visual recovery, and operational efficiencies in the global cataract treatment market, which encompasses over 32 million annual procedures worldwide. In March 2025, LENSAR entered a definitive merger agreement with Alcon, under which Alcon plans to acquire all outstanding shares for $14 per share in cash, plus a contingent value right of up to $2.75 per share based on future procedure milestones, valuing the deal at approximately $356 million initially and up to $430 million; the transaction, aimed at bolstering Alcon's femtosecond laser-assisted cataract surgery portfolio, remains pending regulatory and stockholder approvals, with closure anticipated in mid-to-late 2025.
Company News
LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026
Cedar Grove Capital Q3 2026 Portfolio Update
LENSAR Q2 Earnings Call Highlights
LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
LENSAR Shareholders Re-Elect Directors, Back Executive Pay at 2026 Annual Meeting
LENSAR Q1 Earnings Call Highlights
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
Head-To-Head Review: LENSAR (NASDAQ:LNSR) vs. Edwards Lifesciences (NYSE:EW)
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Contrasting DexCom (NASDAQ:DXCM) and LENSAR (NASDAQ:LNSR)
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
BYND And LNSR Set The Tone Tuesday
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
LENSAR® Provides Update on Pending Acquisition by Alcon
Credit Industriel ET Commercial Sells 45,117 Shares of LENSAR, Inc. $LNSR
Head to Head Analysis: LENSAR (NASDAQ:LNSR) versus enVVeno Medical (NASDAQ:NVNO)